NASDAQ$NRC
NRC Health · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported second quarter results with revenue slightly decreasing compared to the previous year.
NRC Health announced its second quarter 2024 results, with revenue of approximately $35 million and earnings per diluted share of $0.26. The company also completed an amendment to its credit agreement and acquired NOBL Health.
- Revenue for the quarter was approximately $35 million, compared to $36 million in the same quarter of 2023.
- Earnings per diluted share were $0.26, down from $0.29 in the second quarter of 2023.
- Net indebtedness was approximately $42 million as of June 30, 2024.
- Total recurring contract value (TRCV) was approximately $138 million at June 30, 2024.
Headline financials
Revenue & EPS history
NRC · Revenue · Quarterly
$35M
Forward guidance
The company has elected to include strategic updates normally discussed in earning calls to a broader group of current and potential stockholders via its quarterly earnings releases.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.9%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-0.3%
Avg return
30 days after
54%
28 / 52 earnings
Positive
+16.1%
Q3 2025
Best reaction
-19.9%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.6% | +7.9% | +16.0% | |
| Q4 2025 | -19.9% | -27.2% | -35.9% | |
| Q3 2025 | +16.1% | +17.0% | +51.2% | |
| Q2 2025 | +2.1% | +4.8% | +6.7% | |
| Q1 2025 | +7.0% | +7.6% | +20.2% | |
| Q4 2024 | -11.9% | -11.0% | -22.6% | |
| Q3 2024 | +2.6% | -2.1% | +4.5% | |
| Q2 2024 | -11.7% | -9.3% | -7.2% | |
| Q1 2024 | -15.3% | -11.6% | -23.7% | |
| Q4 2023 | +2.2% | +0.6% | +1.7% | |
| Q3 2023 | -1.9% | -0.3% | -1.1% | |
| Q2 2023 | +2.2% | -0.4% | -2.6% | |
| Q1 2023 | -8.3% | -5.2% | -1.2% | |
| Q4 2022 | +4.8% | +5.3% | -1.8% | |
| Q3 2022 | -13.5% | -8.3% | -3.5% | |
| Q2 2022 | -4.1% | -7.4% | -12.8% | |
| Q1 2022 | -5.3% | -3.6% | +5.0% | |
| Q4 2021 | -1.5% | -4.5% | -4.7% | |
| Q3 2021 | +6.7% | +6.7% | -8.1% | |
| Q2 2021 | -0.8% | -0.2% | +1.6% | |
| Q1 2021 | -10.2% | -5.1% | -7.0% | |
| Q4 2020 | -0.7% | -3.9% | +0.3% | |
| Q3 2020 | +1.8% | -0.1% | -7.8% | |
| Q2 2020 | -4.1% | -1.0% | -3.0% | |
| Q1 2020 | +4.6% | +10.3% | +12.7% | |
| Q4 2019 | +0.3% | +1.8% | -36.0% | |
| Q3 2019 | -0.4% | +0.2% | +7.5% | |
| Q2 2019 | +3.0% | +2.6% | +1.0% | |
| Q1 2019 | +7.1% | +13.1% | +26.5% | |
| Q4 2018 | +0.6% | +2.7% | +0.2% | |
| Q3 2018 | +3.5% | +2.4% | +4.8% | |
| Q2 2018 | -0.3% | -0.3% | +2.4% | |
| Q1 2018 | +7.3% | +5.5% | +5.4% | |
| Q4 2017 | -7.4% | -7.9% | -9.7% | |
| Q3 2017 | -10.1% | -11.5% | -7.7% | |
| Q2 2017 | +0.9% | +1.7% | +9.9% | |
| Q1 2017 | +0.8% | -3.4% | -3.0% | |
| Q4 2016 | -3.0% | -4.9% | +0.5% | |
| Q3 2016 | -4.6% | -1.0% | +5.2% | |
| Q2 2016 | +0.3% | +2.3% | +2.2% | |
| Q1 2016 | +2.0% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +1.5% | — | — | |
| Q2 2015 | -2.4% | — | — | |
| Q1 2015 | +1.3% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | +0.9% | — | — | |
| Q2 2014 | +3.8% | — | — | |
| Q1 2014 | +3.9% | — | — | |
| Q4 2013 | +5.1% | — | — | |
| Q3 2013 | +1.0% | — | — | |
| Q2 2013 | -1.2% | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q4 2009 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro